地昔帕明刺激肾上腺素能活性联合G-CSF增强多发性骨髓瘤造血干细胞及祖细胞动员:一项先导研究
这项开放标签单臂先导研究在多发性骨髓瘤自体干细胞移植患者中评估地昔帕明联合G-CSF动员造血干细胞的安全性和疗效。10例入组中6例完成方案,均达到5×10^6 CD34+细胞/kg采集目标,中位采集1.5次,2例需加用普乐沙福(16%);历史对照组13例中11例(85%)达标,中位采集2次,7例需普乐沙福(54%)。作者认为该联合方案安全,并提示动员效果优于单用G-CSF,可能需要进一步研究。
要点
- 地昔帕明100 mg每日一次共7天,自G-CSF给药前4天(D-3)开始与G-CSF联用。
- 完成方案的6例均达到5×10^6 CD34+细胞/kg,中位采集1.5次,2例需加用普乐沙福(16%)。
- 历史对照组13例中11例(85%)达标,中位采集2次,7例需普乐沙福(54%)。
核心结论
- 地昔帕明联合G-CSF是安全的,并提示动员效果优于单用G-CSF,可能提供一种替代动员方式,但需要进一步研究。
研究设计与样本
- 开放标签单臂先导研究,纳入接受自体干细胞移植的多发性骨髓瘤患者,评估地昔帕明联合G-CSF动员造血干细胞的安全性和疗效。
- 主要终点为联合方案的安全性(包括植入动力学),次要终点为采集≥5×10^6 CD34+细胞/kg的患者比例。
- 结局与同一时间段内接受G-CSF动员的多发性骨髓瘤历史匹配对照进行比较。
主要发现
- 10例入组患者中6例完成方案,副作用轻微。
- 完成方案的6例均达到5×10^6 CD34+细胞/kg采集目标,中位采集1.5次,2例需加用普乐沙福(16%)。
- 历史对照组13例中11例(85%)达到5×10^6 CD34+细胞/kg目标,中位采集2次,7例需普乐沙福(54%)。
关键数值与推荐
- 所有研究患者接受地昔帕明100 mg每日一次共7天,自G-CSF给药前4天(D-3)开始,与G-CSF联用共7天。
- 采集目标为5×10^6 CD34+细胞/kg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic stem cell (HSC) release is positively regulated by the sympathetic nervous system through the β3 adrenergic receptor. Preclinical studies have demonstrated that the combination of desipramine and G-CSF resulted in improved HSC mobilization. Here, we present the results of an open-label single-arm pilot study in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) to assess the safety and efficacy of desipramine combined with G-SCF to induce HSC mobilization. The primary endpoint was safety of the combination including engraftment kinetics. The secondary endpoint was the proportion of patients who collected ≥5 × 106 CD34+ cells/kg. Outcomes were compared with historical matched controls during the same time period with multiple myeloma mobilized with G-CSF. All study patients received desipramine 100 mg daily for 7 days, starting 4 days prior to G-CSF administration (D-3) and continued taking it along with G-CSF for a total of 7 days. Six of ten patients enrolled completed the protocol with minimal side effects. All of them achieved the target collection of 5 × 106 CD34 cells/kg in a median of 1.5 apheresis session with two patients needing additional plerixafor (16%), while 11 out of 13 patients (85%) achieved the target of 5 × 106 CD34 cells/kg in the historical control group in a median of 2 apheresis procedures and seven patients needed plerixafor (54%). The combination of desipramine and G-CSF is safe and signals improved mobilization over G-CSF alone, providing a possible alternative means of mobilization that needs further investigation.
引用
- Shastri A, Budhathoki A, Barta SK, et al. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study. Am J Hematol. 2017. PMID: 28675459. doi:10.1002/ajh.24843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。